Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195479 · ClinicalTrials.gov registry record · Phase 3
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 706
- Enrollment target
NCT02195479 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 706 participants.
The verdict
NCT02195479, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 706 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of daratumumab to velcade (bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy and autologous stem cell transplant (ASCT).
Interventions
- DRUG Melphalan
- DRUG Dexamethasone
- DRUG Prednisone
- DRUG Velcade
- DRUG Daratumumab IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 706 participants |
| Start Date | 2014-12-09 |
| Est. Completion | 2024-08-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02195479
The ClinicalTrials.gov registry entry for NCT02195479 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 706 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT02195479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02195479 about?
NCT02195479 is a clinical study titled "A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma". The purpose of this study is to determine if the addition of daratumumab to velcade (bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy an...
What is the current status of trial NCT02195479?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 706 participants. The study started on 2014-12-09. Estimated completion is 2024-08-07.
What interventions are being tested in trial NCT02195479?
The interventions under investigation include: Melphalan (DRUG), Dexamethasone (DRUG), Prednisone (DRUG), Velcade (DRUG), Daratumumab IV (DRUG).
Who is sponsoring clinical trial NCT02195479?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.